Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in combination with pegenzileukin in relapsed or refractory multiple myeloma
2024-514990-23-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of isatuximab and pegenzileukin in multiple myeloma (MM), sponsored by Sanofi. Primary endpoints: Recommended dose of novel agents in combination with isatuximab and Overall response rate (ORR) - Part 2. Started Oct 2024; status: completed.
02
Drugs
isatuximabpegenzileukin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514990-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514990-23-00.